On June 15, 2026, the FDA expanded Tzield (teplizumab) accelerated approval for certain children ages 8–17 with newly diagnosed stage 3 type 1 diabetes. Here’s who may qualify, what “delay” means, and the key safety cautions families should plan for.
On June 12, 2026, the FDA cleared the first over-the-counter continuous glucose monitor (CGM) for children age 2+ who do not use insulin. Here’s what the device can do, the key safety limits FDA emphasized, and practical steps for families to use glucose data responsibly.
CMS updated its local Medicare coverage policy for implantable CGMs on June 25, 2026. Here’s what eligibility typically depends on, what to document for your visit, and key safety/practical limits.
A May 26, 2026 FDA-posted correction affects certain Omnipod 5, DASH, and Eros Pod lots. Here’s how to check your lot, what to do if you have an affected Pod, and which high-blood-sugar or DKA warning signs need urgent care.
The FDA’s June 12 clearance expands an over-the-counter glucose monitor to children ages 2 and older who do not use insulin. It may make glucose tracking easier for some families, but it still has important limits on low-sugar warnings, insulin use, dialysis, and insurance coverage.
CDC says people with a family member who has type 1 diabetes should be offered screening, starting at age 2. With newer FDA-approved uses for Tzield, a positive result can now lead to more specific follow-up discussions, though screening still has important limits.
If you use a TRUE METRIX blood glucose meter, the FDA says to keep testing but switch to another glucose-testing method as soon as you can. The concern is an E-5 error code that can mean either a very high blood sugar reading or a strip problem, which could delay treatment or lead to the wrong response.
The CDC’s April 17, 2026 guidance makes type 1 diabetes screening easier to understand for families at higher risk. The key point is that type 1 diabetes can develop in stages before symptoms appear, and earlier testing may help some people notice problems sooner and reduce the chance of a missed diagnosis.
Diabetes can develop quietly, and prediabetes is common enough that many people may be at risk without realizing it. New CDC guidance also emphasizes earlier type 1 diabetes screening for some people with higher risk, including children.
The FDA says phone settings or software problems can disrupt diabetes device alerts, raising the risk of missed low blood sugar warnings and delayed treatment.
Diabetes can raise the risk of bleeding gums, dry mouth, infection, and slower healing. Here’s how to spot trouble early and protect your mouth every day.
Gum disease is chronic inflammation that can quietly weaken tooth support. Here is what bleeding, bone loss, and long-term maintenance really mean.
A new Medicare study suggests the $35 insulin cap is lowering patients’ costs. But supplies, other diabetes expenses, and gaps outside Medicare still matter.
The 2025-2030 U.S. Dietary Guidelines put more weight on whole foods and less on added sugar and heavily processed foods. Here’s what changed.
FDA’s 2026 GLP-1 crackdown targets compounded or illegally marketed products, not approved brands. Here’s how patients can verify what they’re taking.
Medicare changed how it pays for many skin substitute products used in diabetic foot ulcers in 2026, but it did not broadly stop covering care. Here’s what the change may mean for access, treatment conversations, and when to seek help.
The short answer is not yet. Medicare has selected Ozempic, Rybelsus, and Wegovy for drug price negotiation, but the negotiated Medicare price is not scheduled to begin until January 1, 2027. Here is what changed in 2026, why the timeline is confusing, and why your own costs can still vary by plan.
Medicare covers some diabetes-related foot care in 2026, but not unlimited routine foot care for everyone. Here’s who qualifies for Part B foot exams and treatment every 6 months, what therapeutic shoes may be covered, what you may pay, and which symptoms should be checked sooner.
The FDA has classified a recall for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors as Class I, its most serious recall type. The issue is falsely low glucose readings from some sensor lots. Here is what is affected, what is not, how to check your sensor, and what to do if a reading does not match how you feel.
A 2026 Medicare policy update gives eligible beneficiaries more ways to join the Medicare Diabetes Prevention Program, including live online and on-demand sessions through December 31, 2029. Here’s who qualifies, what the program includes, what Medicare pays, and why the access change matters for older adults with prediabetes.
The FDA has issued recent safety communications about compounded versions of popular GLP-1 drugs such as semaglutide and tirzepatide, warning of dosing errors, ingredient differences, and potential contamination. Here’s what patients and families should understand about the risks, legal limits, and how to protect themselves.
The American Diabetes Association’s 2026 Standards of Care update national guidance on glucose monitoring, medications, heart and kidney protection, and mental health screening. Here’s what changed — and what it means for patients across the United States.
End of content
End of content
